2.110EUR+1.69%Mkt Cap: 59.24M EURP/E: —Last update: 2026-05-29
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead p…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap59.24M EUR
Enterprise Value48.31M EUR
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.62M EUR
Revenue/Share—
Last Price2.110 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees13
CountryFI
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.05
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-30.14
EPS (TTM)-0.28
EPS (Forward)-0.21
52W Range
1.22034% of range3.870
52W High3.870 EUR
52W Low1.220 EUR
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE392.28%
ROA-248.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.10M EUR
CapEx (TTM)—
FCF Margin—
FCF Yield-5.75%
Net Debt-2.53M EUR
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.01
Current Ratio2.92
Quick Ratio2.88
Book Value/Sh-0.0700 EUR
Cash/Share0.1080 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)2.400 EUR
Target Range2.400 EUR – 2.400 EUR
# Analysts1
Ownership
Shares Out.26.50M
Float14.25M
Insiders24.99%
Institutions24.43%
Technical
SMA 501.760 (+19.9%)
SMA 2002.005 (+5.2%)
Beta0.63
S&P 52W Chg27.94%
Avg Vol (30d)25.79K
Avg Vol (10d)28.33K
Technical Indicators
RSI (14)72.9
MACD0.0468
MACD Signal0.0138
MACD Hist.+0.0330
BB Upper1.987 EUR
BB Middle1.797 EUR
BB Lower1.608 EUR
BB Width21.06%
ATR (14)0.1125 EUR
Vol Ratio (20d)1.59x